Objective: There are no validated approaches to predict benefit from adjuvant chemotherapy for resected patients with non-small-cell lung cancer (NSCLC). The aim of this study was to translate a 15-gene mRNA expression profile published by Zhu shown to be prognostic and predictive of benefit, into a readily applicable immunohistochemistry (IHC) panel.
Methods: For seven of the genes in the gene expression profile (GEP) for which suitable commercial antibodies were available, we semiquantitatively assessed the IHC expression and prognostic significance for 173 patients treated at the Saint John Regional Hospital (SJRH). Cut-offs for high and low expression were defined for each marker and applied to IHC scores from 291 of the 482 patients in JBR.10, including patients on both the adjuvant chemotherapy and observation arms. The prognostic and predictive value of these markers on overall survival (OS) or recurrence-free survival (RFS) was assessed by Cox regression models.
Results: In the SJRH cohort, in 62 patients with resected stage II-III NSCLC, the prognostic significance of IHC assays for four proteins were concordant with Zhu's GEP results. Low FOSL2 (OS, HR=0.15; p=0.0001; RFS, HR=0.14; p<0.0001) and high STMN2 (RFS, HR=2.501; p=0.0197) were adverse prognostic factors. Low ATP1B1 and low TRIM14 expression trended toward worse OS and RFS. Validation of these markers with JBR.10 patients failed to show prognostic significance either individually or in combined risk classifications. Additionally, the interaction between these markers and chemotherapy treatment in predicting OS (FOSL2, p=0.52; STMN2 p=0.14; ATP1B1, p=0.33; TRIM14, p=0.81) or RFS (FOSL2, p=0.63; STMN2, p=0.12; ATP1B1, p=0.66; TRIM14, p=0.57) did not reach significance, individually or in combination panels.
Conclusions: Zhu's GEP could not be translated into an IHC panel predictive of benefit from adjuvant chemotherapy. Future predictive biomarker analysis in the adjuvant NSCLC setting may need to focus on novel therapies.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7174014 | PMC |
| http://dx.doi.org/10.1136/esmoopen-2020-000679 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Potential Clinical Relevance of Procoagulant Microparticles as Biomarkers of Blood Coagulation in Breast Cancer: A Systematic Review.
Asian Pac J Cancer Prev
January 2025
Research Center for Noncommunicable Disease, Jahrom University of Medical Sciences, Jahrom, Iran.
Background: Breast cancer (BC) is a global challenge that affects a large portion of individuals, especially women. It has been suggested that microparticles (MPs) can be used as a diagnostic, prognostic, or therapeutic biomarker in various diseases. Moreover, MPs are known to elevate in cancer cases.
View Article and Find Full Text PDFWeight censorial score: estimation of the weight loss during concurrent chemo-radiotherapy in nasopharyngeal carcinoma patients by image features predicts prognosis.
Radiol Med
January 2025
Department of Health Technology and Informatics, The Hong Kong Polytechnic University, Kowloon, Hong Kong.
Purpose: Bodyweight loss is commonly found in Nasopharyngeal Carcinoma patients during Concurrent Chemo-radiotherapy (CCRT) and has implications for treatment decisions. However, the prognostic value of this weight loss remains uncertain. We addressed it by proposing a novel index Weight Censorial Score (WCS) that characterizes the patient-specific CCRT response on actual to estimated weight loss.
View Article and Find Full Text PDFASO Visual Abstract: Adjuvant Cytotoxic Chemotherapy May Not Be Associated with a Survival Advantage for Resected Intrahepatic Cholangiocarcinoma.
Ann Surg Oncol
January 2025
Department of Surgery, Duke University Medical Center, Durham, NC, USA.
Perioperative chemotherapy strategies in diffuse gastric cancer.
World J Gastrointest Surg
January 2025
Department of Surgery, Division of Endocrine & Minimally Invasive Surgery, Weill Cornell Medical College, New York-Presbyterian Hospital, New York, NY 10128, United States.
This study reviews the findings of a recent study by Li , which demonstrated that perioperative chemotherapy benefits patients with diffuse-type gastric cancer compared to surgery alone. Despite potential biases, the study supports the inclusion of perioperative chemotherapy in treatment guidelines. Neoadjuvant and adjuvant chemotherapy may also provide similar survival outcomes, allowing for flexible treatment planning.
View Article and Find Full Text PDFImproving predictive accuracy of early recurrence in pancreatic ductal adenocarcinoma: Role of postoperative serum tumor markers.
World J Gastrointest Surg
January 2025
Department of Supportive Oncology, Atrium Health Levine Cancer, Charlotte, NC 28204, United States.
In a recent study by He , the nomogram integrates postoperative serum tumor markers such as carbohydrate antigen 19-9 and carcinoembryonic antigen, thereby improving the accuracy of identifying high-risk patients compared to relying solely on preoperative markers, which has significant implications for customizing adjuvant therapy and potentially improving outcomes for this aggressive form of cancer. However, the study's single-center design and short follow-up period may limit the generalizability of its findings and potentially introduce reporting bias. Future studies could consider additional confounding factors, such as adjuvant chemotherapy and variations in surgical techniques, to improve the model's accuracy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!